New clinical trials are examining tirzepatide and semaglutide.
The U.S. Food and Drug Administration is warning consumers that off-brand forms of the medications could be unsafe.
Kisqali is already FDA approved, but the new data means it could be used in a broader range of patients.
How much this will impact a nationwide overdose crisis is not clear, even though better access to naloxone is a priority.
The American Academy of Pediatrics said it's a disease with genetic, social and environmental factors.
Fentanyl deaths are rising, especially in Harris County, but researchers say they've found a possible solution to this epidemic.